Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading Volume

Shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) saw an uptick in trading volume on Wednesday . 2,364 shares were traded during mid-day trading, a decline of 93% from the previous session’s volume of 32,151 shares.The stock last traded at $23.00 and had previously closed at $24.48.

A number of equities research analysts recently weighed in on the stock. SEB Equity Research began coverage on shares of Calliditas Therapeutics AB (publ) in a research note on Wednesday, July 7th. They set a “buy” rating on the stock. Zacks Investment Research cut Calliditas Therapeutics AB (publ) from a “buy” rating to a “hold” rating in a research note on Friday, August 13th. Finally, SEB Equities started coverage on Calliditas Therapeutics AB (publ) in a report on Wednesday, July 7th. They set a “buy” rating for the company.

The firm has a 50 day simple moving average of $28.52 and a two-hundred day simple moving average of $28.67. The stock has a market cap of $591.73 million, a price-to-earnings ratio of -8.23 and a beta of 2.61.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CALT. Advisory Services Network LLC bought a new position in Calliditas Therapeutics AB (publ) during the 2nd quarter worth $99,000. NEXT Financial Group Inc acquired a new position in Calliditas Therapeutics AB (publ) during the 2nd quarter worth about $131,000. Citadel Advisors LLC acquired a new position in Calliditas Therapeutics AB (publ) during the 1st quarter worth about $264,000. Tudor Investment Corp Et Al acquired a new position in shares of Calliditas Therapeutics AB (publ) in the 1st quarter valued at about $380,000. Finally, Deutsche Bank AG lifted its stake in shares of Calliditas Therapeutics AB (publ) by 1.8% in the 2nd quarter. Deutsche Bank AG now owns 71,531 shares of the company’s stock valued at $2,107,000 after purchasing an additional 1,295 shares during the period. 4.24% of the stock is owned by institutional investors.

Calliditas Therapeutics AB (publ) Company Profile (NASDAQ:CALT)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy.

Recommended Story: Trading Options- What is a Strangle?

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.